Search
Givosiran
go.drugbank.com/drugs/DB15066ApprovedGivosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. … [A187991] Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigational[Peginterferon Alfa-2a]) in Patients With CHD. … [A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead.
Varenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalA full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. … The FDA said it is keeping the black box in place at least until the results of the trial are announced.
Levoketoconazole
go.drugbank.com/drugs/DB05667ApprovedIt possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate. … Still, toxicity has limited its use, notably hepatic toxicity and a tendency to prolong the QT interval.[A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].
Human botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115ApprovedInfant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. … [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.
Synonyms: Human botulinum neurotoxin A/B immune globulinRopeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242005] Ropeginterferon alfa-2b is a next-generation mono-pegylated type I interferon produced from proline-IFN-α-2b in _Escherichia coli_ that has high tolerability and a long half-life. … [A242010, A242015] Ropeginterferon alfa-2b was approved by the FDA on November 12, 2021, and is currently marketed under the trademark BESREMi by PharmaEssentia Corporation.[L39170]
Zidebactam
go.drugbank.com/drugs/DB13090ApprovedZidebactam is a diazabicyclooctane that acts both as a beta-lactamase inhibitor and as an antibacterial in its own right, selectively binding penicillin-binding protein 2. … [L63350,L63932] The combination is aimed at multidrug-resistant Gram-negative infections, a group for which treatment options are limited and where resistance to carbapenems has narrowed the available
AG0301-COVID19
go.drugbank.com/drugs/DB15856InvestigationalThe candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. … The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA vaccine product.
QXL138AM
go.drugbank.com/drugs/DB18552InvestigationalQXL138AM is a masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a. It binds the CD138 protein on the surface of the tumour cells.
Synonyms: Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2aMe-4(18F)DG
go.drugbank.com/drugs/DB19207InvestigationalMe-4(18F)DG is under investigation in clinical trial NCT05558904 (An Investigational Scan (Me-4fdg PET/CT) for the Detection of Sodium-glucose Transport for Early Diagnosis of Lung Cancer).
Synonyms: -d-glucopyranoside, methyl 4-deoxy-4-(fluoro-18f)-, -methyl-4-(F-18)-fluoro-4-deoxy-d-glucopyranoside